Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes.
Dermal dendrocytes (DDs) are dendritic cells that exhibit immunoreactivity for factor XIIIa, and are frequently found in conjunction with basal cell carcinomas (BCCs). Imiquimod was applied to 12 superficial BCCs every 3 days for 8 weeks. One week after completion of treatment, seven lesions appeared to have resolved, while five displayed evidence of residual BCC. Prior to initiation of treatment, the seven imiquimod-responsive BCCs were surrounded by numerous DDs, whereas the five imiquimod-resistant BCCs had fewer DDs next to them at the time of entry into the study. It appears that the pretreatment density in DDs may affect the efficacy of imiquimod in eradicating skin tumours.
Quatresooz
P
P
Department of Dermatopathology, University Hospital Sart Tilman, Liège, Belgium.
Piérard
G E
GE
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000287:Administration, Topical; D000368:Aged; D000634:Aminoquinolines / Q000008:administration & dosage*; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology*; D005153:Facial Neoplasms / Q000188:drug therapy*; D026122:Factor XIIIa / Q000276:immunology*; D006801:Humans; D000077271:Imiquimod; D007150:Immunohistochemistry; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D026122:Factor XIIIa; D000077271:Imiquimod